Drugs that inhibit IGF-1 receptor IGF-1R were encouraging in early trials, but predictive biomarkers were lacking and the drugs provided insufficient benefit in unselected patients. In this study, we used genetic screening and downstream validation to identify the WNT pathway element DVL3 as a mediator of resistance to IGF-1R inhibition. Sensitivity to IGF-1R inhibition was enhanced specifically in vitro and in vivo by genetic or pharmacological blockade of DVL3. In breast and prostate cancer cells, sensitization tracked with enhanced MEK-ERK activation and relied upon MEK activity and DVL3 expression. Mechanistic investigations showed that DVL3 is present in an adaptor complex that links IGF-1R to RAS, that includes Shc, Grb2, SOS and the tumor suppressor DAB2. Dual DVL and DAB2 blockade synergized in activating ERKs and sensitizing cells to IGF-1R inhibition, suggesting a nonredundant role for DVL3 in the Shc-Grb2-SOS complex. Clinically, tumors that responded to IGF-1R inhibition contained relatively lower levels of DVL3 protein than resistant tumors, and DVL3 levels in tumors correlated inversely with progression-free survival in patients treated with IGF-1R antibodies.
Introduction
Type 1 insulin-like growth factor receptor (IGF-1R) signals via recruitment of adaptors including insulin receptor substrate-1 (IRS-1) and Shc to drive proliferation, invasion and cell survival (1) . In the clinical and experimental setting, low IGF bioactivity protects from tumor development and metastasis, suggesting that IGFs provide a potent pro-tumorigenic signal (2, 3) . In early clinical trials, IGF-1R inhibitory drugs induced objective regressions, some dramatic and durable, as monotherapy in Ewing sarcomas and other uncommon tumors, and with chemotherapy or targeted agents in common cancers (4) (5) (6) (7) (8) (9) . However, these encouraging early reports have not translated to Phase 3 benefit in unselected patients (10) . Clearly, a better understanding of IGF-1R biology is required if this therapeutic approach is to be successful. Key priorities are to understand what makes tumors resistant to IGF-1R inhibition, use this information to target these drugs to potentially responsive patients, and select rational treatment combinations for clinical testing. To address these issues, we used genetic screening and downstream validation to identify novel determinants of resistance to an IGF-1R antagonist. incorporating BamH1 and Xho1 sites respectively (underlined), digested with BamH1 and Xho1 (New England Biolabs), cloned into BamHI-XhoI digested pHRSIN-CSGW HIV vector, and after verification of the insert by DNA sequencing, used for virus production as described (11) . Western blotting, immunoprecipitation and pulldown assays were performed using reagents described in (12) , Supplementary Methods, and Table S1 .
siRNA screens Screens were performed as (13, 14) , using kinase siRNA library (siARRAY, targeting 779 known and putative human protein kinases; Dharmacon) containing SMARTPools of four siRNAs targeting each transcript, and human DNA Repair siRNA Set V1.0 siRNA library (Qiagen), together with siPLK1 and Allstars siRNA as positive and negative controls respectively. Cells were reverse-transfected with 50nM siRNAs using Dharmafect 1 reagent for DU145 and Dharmafect 3 for MCF-7. Two days later, cells were exposed to vehicle (0.01% DMSO) or AZ1223580 at the GI 50 for 5 days, and viability was assessed by
CellTiter Glo (CTG) assay (Promega). Duplicate primary screens were analyzed to derive Z' factors (dynamic range) and Z-scores (effect of siRNA on viability, corrected for within/between plate variation), as described (14) (15) (16) Table S2 . Data were analyzed to generate log2 surviving fractions as the final score for the effect of IGF-1R inhibition on viability; scores < -0.2 were regarded as significant, as described (13, 14) . Hits were validated by siRNA-transfection as above, analyzing after 48 hours by western blot or quantitative reverse-transcription PCR (qRT-PCR, with primers listed in Table S3 ), or treating with solvent or AZ12253801 and assaying for viability after 5 days or clonogenic survival after 10-20 days. Pooled data from ш3 independent experiments were curve-fitted using GraphPad Prism v5 to interpolate GI 50 and SF 50 (concentrations inhibiting 50% of growth or survival).
Immunofluorescence, immunohistochemistry
Cells underwent immunofluorescent staining using ERK antibody (#4695, Cell Signaling Technology).
IHC used DVL3 antibody 4D3 (Santa Cruz; see Supplementary Methods).
Xenografts
As detailed in Supplementary Methods, mice bearing DU145 xenografts were randomly allocated to 14 days treatment with 0.05ml solvent (DMSO), 25mg/kg AZ12253801 twice daily, 50mg/kg DVLi once daily or combination treatment.
Results and Discussion

siRNA screens for sensitization to IGF-1R inhibition
IGF-1R over-expression occurs frequently in common cancers, but is a poor predictor of clinical sensitivity to IGF-1R inhibition (10) . Consistent with this, IGF-1R over-expression in PC3 prostate cancer cells did not influence response to IGF-1R tyrosine kinase inhibitor (TKI) AZ12253801 that has ~10-fold selectivity over the insulin receptor (INSR; (17); Figure S1A ). To identify proteins that influence response to AZ12253801, we performed siRNA screens in DU145 prostate cancer and MCF7 breast cancer cells, confirming that AZ12253801 inhibited IGF-1R phosphorylation and cell viability ( Figure   S1B ). Primary screens were performed to deplete ~1000 targets; given our interest in the involvement of IGF-1R kinase in the DNA damage response (12, 18) , we selected siRNA libraries targeting kinaserelated and DNA repair-associated proteins, with positive (siPLK1) and negative (Allstars) control siRNAs, as described (13, 14) . Forty-eight hours after siRNA transfection to allow target depletion, cells were treated with solvent or AZ12253801 at the GI 50 and viability was assayed 5 days later. Duplicate DU145 screens were highly reproducible (R 2 values ш0.8) and sensitive, with Z -factors of 0.23-0.6 (Table S4) indicating good discrimination between positive and negative controls (15) . We calculated drug sensitization Z-scores (13) for each siRNA, rank-ordered siRNAs by Z-score, and selected 54 genes for validation (Table S5 ). Triplicate second-round screens identified 12 putative resistance mediators, including regulators of the cell cycle and DNA damage response, and proteins with poorlycharacterized functions ( Figure 1A ). Seven hits in DU145 screens (CDKN2C, CNKSR1, DUSP5, HUNK, LMTK3, MPP2, DVL3) were also candidate hits in MCF7 cells. Validation in low-throughput format confirmed that depletion of each hit enhanced AZ12253801 sensitivity (Table S6) .
DVL3 mediates resistance to IGF-1R inhibition
Known cross-talk between the IGF and WNT axes (19) (20) (21) Wnts to Frizzled (Fz) receptors, blocking the ɴ-catenin destruction complex (22) . DVL3 was the dominant isoform in both DU145 and MCF7 cells ( Figure 1B) , and depletion of DVL3 but not DVL 1 or 2 sensitized to AZ12253801 ( Figure 1C,D) . Expression of siRNA-resistant FLAG-DVL3 was able to rescue from AZ12253801 sensitization induced by DVL3 siRNA targeting the 3'-UTR of endogenous DVL3 mRNA ( Figure 1E ), suggesting that sensitization by DVL3 depletion was unlikely to be an off-target effect of DVL3 siRNA. As noted above, AZ12253801 can also inhibit the closely-related INSR. While DVL3-depleted DU145 and MCF7 cells were sensitized to IGF-1R depletion, INSR-depleted cells showed no significant reduction in viability upon DVL3 depletion ( Figures 1F, S1C ), supporting the contention that functional interaction between DVL3 and AZ12253801 is related to the ability of AZ12253801 to block IGF-1R. We next tested whether intrinsic sensitivity to IGF-1R inhibition is related to endogenous DVL3 expression. In prostate (n=5) and breast cancer (n=5) cell lines there was no apparent relationship between endogenous DVL3 protein and AZ12253801 GI 50 ( Figure S1D ), perhaps reflecting genotypic differences in these small panels. In a larger sample (n=40) of well-characterized colorectal cancer (CRC) cell lines (23, 24) , mean DVL3 protein levels were significantly lower in cell lines that were sensitive to IGF-1R antibody figitumumab (n=11), compared with cell lines that were moderately (n=8) or highly (n=21) figitumumab resistant ( Figure 1G ), supporting the hypothesis that DVL3 protein is associated with resistance to IGF-1R inhibition. There was no correlation with IGF-1R expression ( Figure   S1E -F), consistent with the unchanged response to AZ12253801 in IGF-1R overexpressing PC3 prostate cancer cells ( Figure S1A ). We also noted lack of correlation between DVL3 protein and mRNA in the CRC cell lines, likely due to post-transcriptional regulation of DVL3 expression (25) , and DVL3 mRNA did not associate with response to figitumumab ( Figure S1G ).
DVL3 depleted cells show enhanced ERK activation
We speculated that the association between DVL3 and resistance to IGF-1R inhibition may reflect cross-talk between the WNT and IGF pathways. Previously, we and others showed that the adaptor protein IRS-1 undergoes IGF-induced interaction with ɴ-catenin, promoting ɴ-catenin stabilization and 
Proximal WNT inhibition mimics effects of DVL3 depletion
Aiming to find a drug that recapitulates effects of DVL3 depletion, we tested compounds that block WNT signalling at different levels. Consistent with a role in Axin stabilization (33) (22) . The small molecule inhibitor DVL-PDZ inhibitor II (DVLi) competitively binds to the cleft of the DVL-PDZ domain, and blocks WNT signaling in Xenopus embryo and PC3 prostate cancer cells (34) . This agent inhibited DVL3 phosphorylation and phenocopied DVL3 depletion, reducing active ɴ-catenin and phospho-S6, activating ERKs in the absence of ligand, and sensitizing to AZ12253801 in viability and clonogenic assays ( Figure 3A-D) . DVLi also sensitized to IGF-1R TKI BMS-754807 that is being evaluated clinically (35); Figure S3D ). We noted evidence for reciprocal sensitization: despite suppressing active ɴ-catenin and mTOR, DVLi alone caused negligible growth inhibition, perhaps related at least in part to ERK activation, but with AZ12253801 caused significant loss of viability ( Figure 3E ).
While the DVLi we used has relatively low potency, the WNT pathway is an intense focus for drug development (34, 36) , offering the prospect of more potent inhibitors in future. Therefore, we used this DVLi to perform proof of principle experiments, testing its ability to influence sensitivity to IGF-1R inhibition in the prostate and breast cancer cell lines we characterized previously ( Figure S1D ). Two prostate cancer cell lines (DU145 and 22Rv1) were sensitized to AZ12253801 by DVL inhibition; both had detectable basal ERK phosphorylation that was enhanced by DVLi ( Figure 3F ). The other three (PC3, LNCaP, LNCaP-LN3) did not manifest detectable basal or DVLi-induced ERK phosphorylation and were not sensitized to AZ12253801 by DVLi. The 5 breast cancer cell lines all showed increased ERK activation and enhanced response to AZ12253801 upon DVL inhibition ( Figure 3G ). Thus 7 of 10 cell lines showed DVLi-induced ERK activation and in each, DVLi enhanced response to IGF-1R inhibition.
Supporting the existence of functional cross-talk between the IGF axis and proximal WNT components, up-regulation of IGF binding protein 5 was shown to mediate growth inhibitory effects of a soluble Wnt inhibitor in murine MMTV-Wnt1-driven tumors (36) . Therefore, to test the potential clinical relevance of our findings, we evaluated IGF-1R and DVL inhibition in mice bearing DU145 prostate cancer xenografts. AZ12253801 or DVLi alone had no significant effects on tumor growth, but growth in the Figure 3H ).
DVL3 regulates IGF-1-induced ERK activation
These data indicate that blockade of proximal WNT signalling enhances sensitivity to IGF-1R inhibition, and suggest that this property tracks with regulation of MEK-ERK signalling (Figures 2A-C, 3F,G) . To characterize this effect further, we performed time-course experiments in DVL-inhibited DU145 cells.
IGF-1 induced rapid activation of IGF-1R and AKT that persisted in control cells for at least 60min, while ERK activation peaked at 10min and resolved to basal levels by 60min ( Figure 4A ). In contrast, there was clear persistence of IGF-induced ERK phosphorylation at 30-60min in cells where DVL3 was inhibited ( Figure 4A ) or depleted ( Figure S4A ). Persistent ERK activation in DVL-inhibited cells was apparent within 4hr of DVLi treatment, and was strikingly enhanced upon IGF-treatment ( Figure 4B ).
An increase in IGF-induced ERK activation was also observed in MCF7 cells ( Figure S4B ). These results support the existence of a link between the ability of DVL3 to influence sensitivity to IGF-1R inhibition, and to attenuate the response of the IGF axis to a mitogenic stimulus via MEK-ERK. Consequently, DVL3 depletion or inhibition creates an environment that is permissive for signalling, recently characterized as 'signalability' (37) . In contrast, DVL inhibition did not influence the response to IGF-1 in PC3 prostate cancer cells that were not sensitized to AZ12253801 by DVLi ( Figure S4C ). To test whether ERK activation is required in order for DVL3 to modify the response to IGF-1R inhibition, we abolished ERK activity using MEK inhibitor AZD6244 ( Figure 4C ). MEK-inhibited DU145 cells showed almost complete rescue from DVLi-induced sensitization to IGF-1R inhibition ( Figure 4D ), suggesting that the ability of DVL3 to regulate MEK-ERK contributes to the sensitization effect.
DVL3 complexes with SHC, Grb2 and SOS to regulate RAS activation
To investigate how DVL3 regulates ERKs we performed RAS activation assays, and found that RAS was activated in DVL-inhibited cells ( Figure 5A ). This contrasts with previously reported WNT:ERK cross-talk 
ͳͳ occuring at more distal WNT signalling nodes, that generates positive feedback between the two pathways (38) . Given that DVL3 depletion did not activate IGF-1R itself (Figures 2A, S4B) , and DVL3-depleted or DVL-inhibited cells showed no change in EGF-induced ERK activation or sensitivity to EGFR inhibitor gefitinib ( Figure S5A,B) , we reasoned that RAS activation in DVL depleted or inhibited cells was unlikely to be initiated at the level of these RTKs.
It is increasingly recognized that mitogenic signals generated by RTKs are integrated by complexes of adaptor and scaffolding proteins, including IRS-1, a well-recognized focus for feedback signalling via ERKs and mTOR-S6 kinase (39) . However, IRS-1 knockdown did not influence AZ12253801 sensitivity or ERK activation induced by DVL inhibition (Supplementary Figure S5C,D) . In contrast, ERK activation in DVL-inhibited cells was suppressed by depletion of the adaptor protein Shc, exchange factor son-ofsevenless (SOS), or growth factor receptor-bound-2 (Grb2; Figure 5B ). ERK activation was not abolished by depletion of IGF-1R ( Figure 5B ), suggesting that the ability of DVL3 depletion or DVL inhibition to activate basal (ligand-unstimulated) MEK-ERK signalling was IGF-1R independent, perhaps induced by another RTK or signalling complex.
These data suggest that DVL3 suppresses signal transduction at the level of the Shc-Grb2-SOS complex.
DVLs were not identified as Grb2 interactors in HEK293 cells (40) , but DVL3 does contain the atypical proline-rich region shown in DVL2 to bind Grb2 and promote canonical WNT signaling (41) . Indeed, complexes containing Grb2 and DVL3 were detectable in DU145 cells by immunoprecipitation and Grb2 pulldown ( Figure 5C, D) . These complexes also contained the putative tumor suppressor Disabled 2 (DAB2), reported to limit RAS activation by competing with SOS for Grb2 binding (42) (43) (44) . Consistent with this role, and with the association between ERK activation and sensitization to IGF-1R inhibition ( Figure 3F ,G, Figure 4D ), DAB2 depletion mimicked DVL3 depletion in sensitizing to AZ12253801 and enhancing IGF-induced ERK activation ( Figure 5E ). DVL3 and DAB2 showed similar binding patterns to individual Grb2 domains ( Figure S5E ), interacting principally with the amino-terminal SH3 domain and (45) . We speculated that DVL3 interacts with Grb2 via DAB2, but found that DAB2-depleted cells still contained DVL3:Grb2 complexes ( Figure S5F ), and could be further sensitized to IGF-1R inhibition by DVLi, with 18-fold reduction in AZ12253801 GI 50 in DAB2-deleted, DVL inhibited cells, compared with 2.8 and 4.6 fold sensitization induced separately by DAB2-depletion or DVL-inhibition ( Figure 5F ).
These data suggest that DVL3 has a different role from DAB2 in regulating signal transduction to RAS.
DVL3 expression in clinical cancers
To investigate the clinical relevance of these findings, we evaluated DVL3 expression in patient tumors. (Table S7) . As a first approach to testing for correlation between DVL3 protein and sensitivity to IGF-1R inhibition, we assessed DVL3 in Ewing sarcomas, reported to be responsive to IGF-1R inhibitor monotherapy (4, 5, 46, 47) , and head and neck squamous cell cancers (HNSCC) that are resistant (48) . The results are shown in Figure 6B , C; all but one of the Ewing sarcomas contained low or no detectable DVL3, and the mean DVL3 staining score was significantly higher in HNSCC (p=0.0033). We then assessed DVL3 protein expression in archival tumors from patients recruited to early phase clinical trials of IGF-1R antibodies figitumumab or AVE164 (9, 48); Table S8 ). Figure 6D shows examples of DVL3 staining in 8 of the trial cases, and Figure 6E shows analysis with respect to progression-free survival (PFS). While there was overlap in DVL3 expression between patients experiencing early progression vs prolonged control, it was notable that of 8 patients achieving prolonged disease control (>84 days, including one partial remission), 6 of these tumors had low DVL3 expression (IPS <5; Table S8 ). PFS was longer in patients whose tumours showed no/low DVL3 (n=9, PFS 137 ± 28 days) compared with patients whose tumors had moderate or In summary, our data identify a role for DVL3 in suppressing signal transduction from IGF-1R to RAS and attenuating response to IGF-1R blockade. We propose that the proportion of potentially- 
ͳͶ responsive patients in IGF-1R trials could be significantly increased by selecting cases with low-DVL3 tumors. Graph: mean ±SEM viability expressed relative to solvent-treated controls, pooled data from 3 independent assays. Inset: western blot to check DVL3 depletion. Graph to right: viability at 100nM AZ12253801 (***p<0.001 by one-way ANOVA). D) DU145 cells were transfected with isoform-specific DVL siRNAs, after 48hr DVLs were measured by qPCR, normalized to GAPDH. Graph shows mean ± SEM DVL3 expression relative to Allstars (AS) transfectants (n=3). Table: AZ12253801 GI 
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